Shares of Veracyte (NASDAQ:VCYT) plummeted by 7.45% in after-hours trading on Monday, following the company's Q4 2024 earnings report that missed analyst estimates on profitability.
The molecular diagnostics company reported adjusted earnings per share of $0.06 for the quarter, falling short of the consensus estimate of $0.11 by a wide margin of 45.45%. While revenue for the period came in at $118.6 million, beating expectations of $116.765 million, the earnings miss overshadowed the top-line beat and weighed heavily on Veracyte's stock price.
Despite the quarterly earnings disappointment, Veracyte's Q4 2024 revenue grew by an impressive 20.78% year-over-year, driven by strong demand for its diagnostic tests. The company also provided guidance for its fiscal year 2025 testing revenue, projecting a range of $470 million to $480 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。